AMENDMENTS TO CLAIMS

This listing of claims will replace all prior versions and listings of claims in this application.

Claim 1 (Currently Amended): A compound of the general formula (I),

General Formula (I)

its derivative, its analog, its tautomeric form, its stereoisomer, its geometric form, its N-exide, its polymorph, or its pharmaceutically acceptable salt, or its pharmaceutically acceptable solvate. wherein

A is may be Carbon only;

wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₄ and R₁₅ may be same or different and may be same or different and each independently represent hydrogen, halogen, oxo, thio, perhaloalkyl, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C1-C12)alkyl, (C2-C12)alkenyl, (C2-C C₁₂)alkynyl, (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C₁-C₁₂)alkoxy, cyclo(C₃-C₇)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, alkylthio, thioalkyl. alkoxycarbonylamino. aryloxycarbonylamino, aralkyloxycarbonylamino. aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, Filed July 26, 2010 alkylguanidino, dialkylguanidino, carboxylic acid and its derivatives, sulfonic acids and its derivatives;

R₁₆ and R₁₇ may be the same or different and each independently represents Hydrogen, substituted or unsubstituted groups selected from linear or branched (C1 - C12) (C1 -C₁₂) alkyl, (C₂-C₁₂) alkenyl, (C₂-C₁₂)alkynyl, (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, aralkyl, heteroaryl or heterocyclylalkyl;

R₁₃ along with either R₁₆ or R₁₇ and the two nitrogen atoms may form a piperazine or diazepine ring, which may be further substituted with R14 and R15; and

n = 1.

- Claim 2 (Currently Amended): A compound according to Claim [[-1]1 which is selected from:
 - 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole:
 - 1-(4-Methylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
 - 1-(4-Bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole:
 - 1-(4-Fluorobenzenesulfonyl)-3-(4-methylipierazin-1-ylmethyl)-5-nitro-1H-indole:
 - 1-(4-Methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
 - 1-(4-Isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole:
 - 1-(2-Bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole:
 - 1-(2-Bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole hydrochloride salt;
 - 1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 Hindole:
 - 4,5,6-Trichloro-1-benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;
 - 4.5.6-Trichloro-1- (4-methylbenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 Hindole;

Atty. Docket No. SUB 0006 US

- 1-(4-Bromobenzenesulfonyl)-4, 5, 6-trichloro-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 4,5, 6-Trichloro-1-(4-isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;
- $1-(2-Bromobenzene sulfonyl)-4,\ 5,\ 6-trichloro-3-\ (4-methyl)piperazin-1-ylmethyl)-1\ H-indole;$
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-4, 5, 6-trichloro-3-(4-methylipiperazin- ylmethyl)-1 H-indole;
- 1-Benzenesulfonyl-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;
- 1-(4-Methylbenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;
- 1-(4-Bromobenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-ylmethyl)-1 H- indole;
- 1-(2-Bromobenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-vlmethyl)-1 H-indole:
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-ylmethyl)-1H-indole;
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-ylmethyl)- 1 H-indole hydrochloride salt;
- 1-(4-methoxybenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-ylmethyl)-1 H- indole;
- 1-(4-Fluorobenzenesulfonyl)-5-methoxy-3- (4-methylpiperazin-1-yimethyl)-1 H-indole:
- 5-Bromo1-(4-fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole:
- 5-Bromo-1- (4-fluorobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole hydrochloride salt;
- 5-Bromo-1- (4-fluorobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole maleate salt;
- 5-Bromo-1- (4-fluorobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole citrate salt:
- 5-Bromo1-(4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-vlmethyl)-1H-indole:
- 5-Bromo-1- (benzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 5-Bromo-1- (4-methylbenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 5-Bromo1-(4-bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole:

Atty. Docket No. SUB 0006 US

- 5-Bromo1-(4-isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole:
- 5-Bromo-1-(2-bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;
- 5-Bromo-1- (2-bromobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole hydrochloride salt:
- 5-Bromo-1-(2-bromo-4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)- 1 Hindole;
- 4-Bromo-1- (4-fluorobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 4-Bromo-1- (4-methoxybenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;
- 4-Bromo-1-(4-isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;
- (1-Benzenesulfonyl-1 H-indol-3-yl)- (4-methylpiperazin-1-yl) methanone:
- [1-(4-Methylbenzenesulfonyl)-1 H-indol-3-yl]- (4-methylpiperazin-1-yl) methanone:
- [1-(4-Isopropylbenzenesulfonyl)-1 H-indol-3-yl]- (4-methylpiperazin-1-yl) methanone;
- [1-(2-Bromobenzenesulfonyl)-1 H-indol-3-vI]- (4-methylpiperazin-1-vI) methanone:
- [1-(2-Bromo-4-methoxybenzenesulfonyi)-1 H-indol-3-yl]- (4-methylpiperazin-1- yl) methanone:
- (1-Benzenesulfonyl)-5-nitro-1- H-indol-3-yl)- (4-methylpiperazin-1-yl) methanone;
- [1-(4-Methylbenzenesulfonyl)-5-nitro-1 H-indol-3-yl]- (4-methylpiperazìn-1- yl) methanone;
- [1-(4-Fluorobenzenesulfonyl)-5-nitro-1 H-indol-3-yl]- (4-methylpiperazin-1- yl) methanone:
- [1-(4-Bromobenzenesulfonyl)-5-nitro-1H-indol-3-vl]-(4-methylpiperazin-1- vl) methanone:
- [1-(4-Isopropylbenzenesulfonyl)-5-nitro-1 H-indol-3-yl]- (4-methylpiperazin-1-yl) methanone:
- [1-(2-Bromobenzenesulfonyl)-5-nitro-1 H-indol-3-yl]- (4-methylpiperazin-1- yl) methanone:
- [1-(4-Methoxybenzenesulfonyl)-5-nitro-1 H-indol-3-yl]- (4-methylpiperazin-1- yl) methanone:
- [1-(2-Bromo-4-methoxybenzenesulfonyl)-5-nitro-1 H-indol-3-yl]- (4-methylpiperazin-1- yl) methanone;
- 1-Benzenesulfonyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:

- 1-(4-Fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole:
- 1-(4-Bromobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 1-(4-Isopropylbenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 1-(2-Bromobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 1-(2-Bromobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole hydrochloride salt:
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-3- (4-methylpiperazin-1-vlmethyl)-1 H-indole:
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole hydrochloride salt;
- 1-(4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole:
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-5-chloro-2-methyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;
- 5-Chloro-1-(4-fluorobenzenesulfonyl)-2-methyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 1-(4-Bromobenzenesulfonyl)-5-chloro-2-methyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 5-Chloro-1-(4-Isopropylbenzenesulfonyl)-2-methyl-3-(4-methylpiperazin-1-ylmethyl)- 1 H-indole:
- 1-Benzenesulfonyl-5-chloro-2-phenyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 5-Chloro-1-(4-methylbenzenesulfonyl)-2- phenyl-3- (4-methylpiperazin-1-ylmethyl)- 1 H-indole:
- 1-(Benzenesulfonyl)- 5-fluoro-2-phenyl-3- (4-methylpiperazin-1-yimethyl)-1 H-indole;
- 5-Fluoro-1-(4-methylbenzenesulfonyl)-2-phenyl-3- (4-methylpiperazin-1-ylmethyl)-1H-indole:
- 1-(4-Bromobenzenesulfonyl)-5-chloro-2-phenyl-3-(4-methylpiperazin-1-ylmethyl)-1H-indole:
- 1- (2-Bromobenzenesulfonyl)-5-cyano-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 5-Cvano-1-(4-methoxybenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole:
- 5-Cyano-1-(4-fluorobenzenesulfonyl)-3- (4-methyl piperazin-1-ylmethyl)-1 H-indole:

- Filed July 26, 2010 1-(4-Bromobenzenesulfonyl)-5-cvano-3-(4-methylpiperazin-1-vlmethyl)-1H-indole:
 - 5-Cyano-1-(4-Isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;
 - N-(1- (4-Fluorobenzenesulfonyl)-1 H-indol-3-vl) methyl-N, N', N'-trimethylethylene-1, 2diamine:
 - N-(1- (4-Fluorobenzenesulfonyl)-1 H-indol-3-vl) methyl-N, N', N'-trimethylethylene-1, 2diamine hydrochloride salt;
 - N-(1- (4-Bromobenzenesulfonyl)-5-bromo-1 H-indol-3-vi) methyl-N, N', N'trimethylethylene-1, 2-diamine:
 - N-(1- (4-Bromobenzenesulfonyl)-5-bromo-1 H-indol-3-yl) methyl-N, N', N'trimethylethylene-1, 2-diamine hydrochloride salt:
 - N-(5-Bromo-1-(4-methoxybenzenesulfonyl)1H-indol-3-yl)methyl-N, N', N'trimethylethylene-1, 2-diamine:
 - N-(1-(4-Methoxybenzenesulfonyl)-5-nitro-1H-indol-3-yl)methyl-N. N'. N'trimethylethylene-1, 2-diamine;
 - N-(1- (4-Methoxybenzenesulfonyl)-5-nitro-1 H-indol-3-vl) methyl-N, N', N'trimethylethylene-1, 2-diamine hydrochloride salt;
 - N-(1-(2-Bromobenzenesulfonyl)-5-bromo-1H-indol-3-yl)methyl-N, N', N'trimethylethylene-1, 2-diamine;
 - 1-(2-Bromobenzenesulfonyl)-3- (4- (3-chlorobenzene-1-vl) piperazin-1-vlmethyl)-1 Hindole:
 - 1-(4-Methoxybenzenesulfonyl)-3- (4- (2-methoxybenzene-1-yl) piperazin-1-ylmethyl)- 1 H-indole:
 - 1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4-(2-methoxybenzene-1-yl)piperazin-1vlmethyl)-1 H-indole:
 - 1-(4-Isopropylbenzenesulfonyl)-3- (4- (2-methoxybenzene-1-yl) piperazin-1-ylmethyl)- 1 H-indole;
 - 5-Bromo-1-(4-fluorobenzenesulfonyl)3-(4-(2-methyoxybenzene-1-yl)piperazin-1ylmethyl)-1 H-indole;
 - 5-Bromo-1-(4-methoxybenzenesulfonyl)-3- (4- (2-methoxybenzene-1-yl) piperazin-1ylmethyi)-1 H-indole:
 - 5-Bromo-1-(4-isopropylbenzenesulfonyl)-3-(4-(2-methyoxybenzene-1-yl)piperazin-1vlmethyl)-1 H-indole:
 - 1-(4-Fluorobenzenesulfonyl)-5-methoxy-3-(4-(2-methoxybenzene-1-yl) piperazin-1vlmethy))-1 H-indole:

Attv. Docket No. SUB 0006 US

- 1-(4-Fluorobenzenesulfonyl)-5-methoxy-3-(4-(2-methoxybenzene-1-yl) piperazin-1-ylmethyl)-1 H-indole hydrochloride salt:
- 1-(4-Methoxybenzenesulfonyl)-5-methoxy-3- (4- (2-methoxybenzene-1-yl) piperazin-1-ylmethyl)-1 H-indole;
- 1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3- (4- (2-methoxybenzene-1-yl) piperazin-1-ylmethyl)-1H-indole;
- 1-(4-Fluorobenzenesulfonyl-3-(4-pyridin-2-yl)piperazin-1-ylmethyl)-1H-indole;
- 1-(4-Methoxybenzenesulfonyl)-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;
- 1-(4-Isopropylbenzenesulfonyl)-3-(4-(pyridin-2-yl)piperazin-1-ylmethyl)-1H-indole;
- 1-(2-Bromobenzenesulfonyl)-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 Hindole;
- 5-Bromo-1-(4-fluorobenzenesulfonyl)-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;
- 5-Bromo-1-(4-methoxybenzenesulfonyl)-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;
- 5-Bromo-1-(4-isopropylbenzenesulfonyl)-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;
- 1-(4-Fluorobenzenesulfonyl)-5-methoxy-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;
- 1-(4-Methoxybenzenesulfonyl)-5-methoxy-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;
- 1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3- (4- (pyridin-2-yl) piperazin-1-ylmethyl)- 1 H-indole;
- 1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3- (4- (benzyl) piperazin-1-ylmethyl)-1 H-indole:
- 1-(4-Methoxybenzenesulfonyl)-5-methoxy-3- (4- (benzyl) piperazin-1-ylmethyl)-1 H- indole:
- 1-(4-lsopropylbenzenesulfonyl)-3- (4- (benzyl) piperazin-1-ylmethyl)-1 H-indole:
- 1-(4-Methoxybenzenesulfonyl)-3- (4- (benzyl) piperazin-1-vlmethyl)-1 H-indole:
- 1-(2-Bromo-4-methoxybenzenesulfonyl)- 3- (4- (benzyl) piperazin-1-ylmethyl)-1 H- indole;
- 1-(Benzenesulfonyl)-3-(4-(benzyl)piperazin-1-ylmethyl)-1H-indole:

- 1-(4-Methoxybenzenesulfonyl)-3-2- [1, 4] Diazepan-1-vlmethyl-1 H-indole:
 - (R, S) 1- (1-Benzenesulfonyl-indol-3-yl)-1- (4-methylpiperazin-1-yl) ethane;
 - $(R) \ 1- \ (1-Benzene sulfonyl-indol-3-yl)-1- \ (4-methylpiperazin-1-yl) \ ethane;$
 - (S) 1- (1-Benzenesulfonyl-indol-3-yl)-1- (4-methylpiperazin-1-yl) ethane;
 - (R, S) 1- [1- (4-Methylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;
 - $(R)\ 1-\ [1-\ (4-Methylbenzenesulfonyl)\ indol-3-yl]-1-\ (4-methylpiperazin-1-yl)\ ethane;$
 - (S) 1- [1- (4-Methylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;
 - (R, S) 1-[1-(4-Methoxybenzenesulfonyl) indol-3-yl]-1-(4-methlpiperazin-1-yl) ethane;
 - (R) 1-[1-(4-Methoxybenzenesulfonyl) indol-3-yl]-1-(4-methlpiperazin-1-yl) ethane:
 - (S) 1- [1- (4-Methoxylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;
 - (R, S) 1- [1- (4-Isopropylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane; (R) 1-[1-(4-Isopropylbenzenesulfonyl) indol-3-yl]-1-(4-methylpiperazin-1-yl) ethane;
 - (S) 1- [1- (4-Isopropylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;
 - $\label{eq:local-problem} \mbox{1-(4-Flurobenzenesulfonyl)-1H-indole-3-carboxylic acid N-(N, N-dimethylaminoethyl)-N-methylamide;}$
 - 1-(4-Methoxybenzenesulfonyl)-1H-indole-3-carboxylicacid N- (N, N-dimethylaminoethyl)-N-methylamide;
 - $1\hbox{-}(4\hbox{-lsopropylbenzenesulfonyl})\hbox{-}1 \hbox{ H-indole-3-carboxylic acid N- (N', N'-dimethylaminoethyl)-N-methylamide;}$
 - (R, S) α [1- (4-Methoxybenzenesulfonyl)-1 H-indol-3-yl]- α (4-methylpiperazin-1- yl) acetonitrile;
 - (R) α [1- (4-Methoxybenzenesulfonyl)-1H-indol-3-yl]- α (4-methylpiperazin-1- y,) acetonitrile;
 - (S) α- [1- (4-Methoxybenzenesulfonyl)-1 H-indol-3-yl]-α- (4-methylpiperazin-1- yl) acetonitrile:
 - (R, S) α-[1- (Benzenesulfonyl)-1 H-indol-3-yll-α- (4-methylpiperazin-1-yl) acetonitrile:
 - (R) α- [1- (Benzenesulfonyl)-1 H-indol-3-yl]-α- (4-methylpiperazin-1-yl) acetonitrile :
 - (S) α- [1- (Benzenesulfonyl)-1 H-indol-3-yl]-α- (4-methylpiperazin-1-yl) acetonitrile:
 - (R, S) α [1- (4-Isopropylbenzenesulfonyl)-1H-indol-3-yl]- α (4-methylpiperazin-1-yl)-acetonitrile:

- (R) α -[1- (4-Isopropylbenzenesulfonyl)-1 H-indol-3-yl]- α (4-methylpiperazin-1-yl)-acetonitrile;
- (S) α -[1-(4-Isopropylbenzenesulfonyl)-1H-indol-3-yl]- α -(4-methlipiperazin-1-yl)-acetonitrile:
- 1-(Benzenesulfonyl)-3- (4- (benzyloxycarbonyl)-piperazin-1-yl methyl)-1 H-indole;
- 1-(Benzenesulfonyl)-3- (4H-piperazin-1-ylmethyl)-1 H-indole;
- 1-(4-Methoxybenzenesulfonyl)-3- (4H-piperazin-1-ylmethyl)-1 H-indole
- 1-(4-Isopropylbenzenesulfonyl)-3- (4H-piperazin-1-ylmethyl)-1 H-indole
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-3- (4H-piperazin-1-ylmethyl)-1 H-indole
- 5-Bromo-1- (benzenesulfonyl)-3- (4H-piperazin-1-ylmethyl)-1 H-indole;
- 5-Bromo-1- (4-methoxybenzenesulfonyl)-3- (4H-piperazin-1-ylmethyl)-1 H-indole
- 5-Bromo-1- (4-isopropylbenzenesulfonyl)-3- (4H-piperazin-1-ylmethyl)-1 H-indole
- 5-Bromo-1-(2-bromo-4-methoxybenzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole
- 1-[[1-(4-Isopropylbenzenesulfonyl)-indol-3-yl]methyl] [1, 4] diazepane
- 1-[[1-(2-Bromo-4-methoxybenzenesulfonyl)-indol-3-yl]methyl] [1,4] diazepane
- 1-[(1- (4-methylbenzenesulfonyl)-indol-3-yl] methyl] [1,4] diazepane
- 1-[[5-Bromo-1-(4-Methoxybenzenesulfonyl)-indol-3-yl]methyl][1, 4] diazepane
- 1-[[5-Bromo-1-(4-Isopropylbenzenesulfonyl)-indol-3-yl]methyl][1, 4] diazepane
- 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indol-3-yl]methyl][1, 4] diazepane
- 1-([5-Bromo-l- (4-methylbenzenesulfonyl)-indol-3-yi] methyl] [1,4] diazepane and their pharmaceutically acceptable salts[[,]] and polymorphs-and-solvates.
- Claim 3 (Currently Amended): A pharmaceutical composition comprising either of a pharmaceutically acceptable carrier, a diluent, or excipients or solvate along with a therapeutically effective amount of a compound according to claim[[-]]1, its-derivative, its analoge, its stautomeric forms, its sterioisomers, its geometric forms, its sterioisomers.

polymorphs, or its pharmaceutically acceptable salts, or its pharmaceutically acceptable

solvates.

Claim 4 (Original): A pharmaceutical composition according to claim-3, in the form

of a tablet, capsule, powder, syrup, injectable solution or suspension.

Claims 5-14. Cancelled.

Claim 15 (Currently Amended): A method for the treatment and/or prophylaxis of

clinical conditions such as anxiety, convulsive disorders, obsessive-compulsive disorders,

migraine headache, cognitive memory disorders, ADHD (Attention Deficient

Disorder/Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic

depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse,

panic attacks, sleep disorders and also disorders associated with spinal trauma and/or head

injury which comprises the step of administering to a patient in need thereof, an effective

amount of a compound of general formula (I) as claimed in claim 1.

Claims 16-19. Cancelled.

Claim 20 (Currently Amended): A process for the preparation of a compound of

general formula (I) in accordance with Claim 1 wherein A is Carbon may be -CH2-, -C=O-or-SO2-;

R₁₁ and R₁₂, refer to substitutions on the carbon whenever A is CH₂:

wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{14} and R_{15} may be the same or different

and may be same or different and each independently represent hydrogen, halogen, oxo, thio,

perhaloalkyl, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or

12

Filed July 26, 2010 unsubstituted groups selected from linear or branched (C1-C12)alkyl, (C2-C12)alkenyl, (C2-C₁₂)alkynyl, (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkenyl, bicycloalkenyl, bicycloalkenyl, (C₁-C₁₂)alkoxy. cyclo(C3-C7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl. hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, alkylthio, thioalkyl, aralkyloxycarbonylamino, aminocarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, alkylamidino, dialkylamidino, dialkylaminocarbonylamino, alkylamidino, alkyl carboxylic acid and its derivatives, sulfonic acids and its derivatives;

R₁₆ and R₁₇ may be the same or different and each independently represents Hydrogen. substituted or unsubstituted groups selected from linear or branched (C1-C12)alkyl, (C2-C₁₂)alkenyl, (C₂-C₁₂)alkynyl, (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkenyl, bicycloalkyl, bicycloalkenyl, arvl. aralkyl, heteroarvl or heterocyclylalkyl;

R₁₃ along with either R₁₆ or R₁₇ and the two nitrogen atoms may form a piperazine or diazepine ring,-which may be further substituted with R14 and R15; and

n = 1:

which comprises reacting a compound of formula (IV) given below,

wherein all the symbols are as defined earlier with a compound of formula (V).

U.S. Patent Appln. No. 10/536,618 Response to Office Action dated April 26, 2010 Filed July 26, 2010

Atty. Docket No. SUB 0006 US

where all the symbols are as defined earlier; and X is halogen, preferably-chloro, bromo er-iode.

Claims 21-25 Cancelled.

Claim 26 (Currently Amended): A process according to Claim 20 comprising of carrying out one or more of the following optional steps: i) removing any protecting group; ii) resolving the racemic mixture into pure enantiomers by the known methods and iii) preparing a preparing-a pharmaceutically acceptable salt of a compound of formula (I)-and/or (Iv) preparing a-pharmaceutically-acceptable-prodrug-thereof.

Claims 27-30 Cancelled.

Claim 31 (Original): Novel compounds of general formula (IV) is defined below,

wherein all symbols are as defined earlier.

U.S. Patent Appln, No. 10/536,618 Response to Office Action dated April 26, 2010 Filed July 26, 2010

Atty. Docket No. SUB 0006 US

Claim 32 Cancelled.

Claim 33. (New): A method for the treatment and/or prophylaxis of a cognitive disorder comprising the step of administering to a patient in need thereof, an effective amount of a compound of general formula (I) as claimed in claim 1.

Claim 34. (New): The method of claim 15, wherein said condition is Alzheimer's disease.

Claim 35. (New): The method of claim 15, wherein said condition is schizophrenia.